文献速递乳腺MRUS

基于临床病理变量、超声和MRI的列线图预测接受新辅助化疗的乳腺癌患者病理完全缓解

Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI.
PubMed 文献 · Br J Radiol · 2024-01-01

回顾性纳入2016年1月至2022年6月间术前接受新辅助化疗的607例局部晚期乳腺癌女性,按7:3随机分为训练集425例和测试集182例,收集化疗前后MRI、超声变量及临床病理特征,用单因素和多因素logistic回归筛选预测因子并构建列线图,训练集AUC为0.884,并在测试集验证。

要点

  • 化疗后MRI肿瘤床无强化与pCR显著相关(OR 8.1,P=.003),是阅片重点征象。
  • MRI肿瘤缩小≥50%与pCR显著相关(OR 9.8,P<.001),报告时应量化缩小比例。
  • 列线图整合临床病理、超声和MRI变量,训练集AUC为0.884,辅助早期治疗决策。

核心结论

  • 包含临床病理变量及MRI和超声特征的列线图在预测pCR方面表现良好。

研究设计与样本

  • 回顾性研究,纳入607例术前接受新辅助化疗的局部晚期乳腺癌女性,按7:3随机分为训练集425例和测试集182例,收集化疗前后MRI和超声变量及临床病理特征,用单因素和多因素logistic回归筛选预测因子,在训练集构建列线图,用ROC曲线下面积评估并在测试集验证。

关键影像表现/征象

  • 化疗后MRI肿瘤床无强化与pCR显著相关(OR 8.1,P=.003)。
  • MRI肿瘤缩小≥50%与pCR显著相关(OR 9.8,P<.001)。
  • 化疗后超声肿瘤尺寸小与pCR显著相关(OR 1.0,P=.031)。
  • 化疗后ADC值升高与pCR显著相关(OR 0.3,P=.035)。

诊断标准与关键数值

  • 激素受体阴性(OR 0.3,P<.001)、人表皮生长因子受体2阳性(OR 2.7,P=.001)、化疗后超声肿瘤尺寸小(OR 1.0,P=.031)、MRI肿瘤缩小≥50%(OR 9.8,P<.001)、化疗后MRI肿瘤床无强化(OR 8.1,P=.003)、化疗后ADC值升高(OR 0.3,P=.035)均与pCR显著相关。
  • 列线图训练集AUC为0.884。

临床应用与阅片要点

  • 化疗后MRI评估肿瘤床无强化和肿瘤缩小≥50%对预测pCR有重要价值。
  • 结合临床病理特征(激素受体状态、HER2状态)及超声和MRI变量综合判断。
  • 列线图可为临床医生早期制定治疗决策提供简捷方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To establish a nomogram for predicting the pathologic complete response (pCR) in breast cancer (BC) patients after NAC by applying magnetic resonance imaging (MRI) and ultrasound (US).

METHODS: A total of 607 LABC women who underwent NAC before surgery between January 2016 and June 2022 were retrospectively enrolled, and then were randomly divided into the training (n = 425) and test set (n = 182) with the ratio of 7:3. MRI and US variables were collected before and after NAC, as well as the clinicopathologic features. Univariate and multivariate logistic regression analyses were applied to confirm the potentially associated predictors of pCR. Finally, a nomogram was developed in the training set with its performance evaluated by the area under the receiver operating characteristics curve (ROC) and validated in the test set.

RESULTS: Of the 607 patients, 108 (25.4%) achieved pCR. Hormone receptor negativity (odds ratio [OR], 0.3; P < .001), human epidermal growth factor receptor 2 positivity (OR, 2.7; P = .001), small tumour size at post-NAC US (OR, 1.0; P = .031), tumour size reduction ≥50% at MRI (OR, 9.8; P < .001), absence of enhancement in the tumour bed at post-NAC MRI (OR, 8.1; P = .003), and the increase of ADC value after NAC (OR, 0.3; P = .035) were all significantly associated with pCR. Incorporating the above variables, the nomogram showed a satisfactory performance with an AUC of 0.884.

CONCLUSION: A nomogram including clinicopathologic variables and MRI and US characteristics shows preferable performance in predicting pCR.

ADVANCES IN KNOWLEDGE: A nomogram incorporating MRI and US with clinicopathologic variables was developed to provide a brief and concise approach in predicting pCR to assist clinicians in making treatment decisions early.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang MQ, Liu XP, Du Y, et al. Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI. Br J Radiol. 2024. PMID: 38263817. doi:10.1093/bjr/tqad014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。